Positive results for triamcinolone acetonide SCS for treatment of macular edema associated with non-infectious uveitis.- Clearside Biomedical.

Clearside Biomedical, Inc. has announced positive topline results from its pivotal Phase III clinical trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis. Suprachoroidal CLS-TA is Clearside�s proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye via the suprachoroidal space, or SCS, which is the space located between the choroid and the outer protective layer of the eye known as the sclera.

Clearside enrolled 160 patients in this randomized, controlled, masked Phase III pivotal clinical (�PEACHTREE�) trial . Of the 160 patients enrolled, 96 patients were randomized to the treatment arm to receive two 4.0 mg doses of suprachoroidal CLS-TA 12 weeks apart, and 64 patients were randomized to undergo sham procedures at the same 12-week interval. Patients were evaluated every four weeks for a total of 24 weeks, and a total of 155 patients, or 97% of those enrolled, completed the full evaluation period of the trial. In the PEACHTREE trial, 47% of patients who received suprachoroidal CLS-TA every 12 weeks gained at least 15 letters in best corrected visual acuity (�BCVA�), as measured using the Early Treatment of Diabetic Retinopathy Study (�ETDRS�) scale, from baseline at week 24, compared to 16% of patients who underwent a sham procedure. This improvement, which was the primary endpoint of the trial, was statistically significant (p < 0.001).

Further, in terms of improvements in BCVA, the mean change from baseline was better in the treatment arm than the sham arm at each monthly evaluation. The mean improvement from baseline was maintained throughout the evaluation period, with 9.6 letters gained at week 4 and 13.7 letters at week 24 in the active arm, compared to 1.2 letters at week 4 and 2.9 letters at week 24 in the control arm, respectively.

For the other key secondary endpoint, administration of suprachoroidal CLS-TA resulted in a mean reduction from baseline of 157 microns in central subfield thickness at week 24 in the active arm compared to a 19 micron mean reduction in the sham arm, a result that was also statistically significant (p <0.001).suprachoroidal cls-ta was generally well tolerated with no treatment-related serious adverse events reported in the trial. through 24 weeks corticosteroid-related elevated intraocular pressure adverse events were reported for approximately 11.5 of patients in the cls-ta treatment group compared to no patients in the sham group. detailed results from peachtree will be presented at an upcoming medical conference.>